XML 17 R5.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Condensed Consolidated Statements of Stockholders’ Equity (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
Total
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2022   226,505      
Beginning balance at Dec. 31, 2022 $ 562,904 $ 227 $ 2,099,782 $ (4,765) $ (1,532,340)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net loss (88,015)       (88,015)
Other comprehensive income (loss) 2,841     2,841  
Issuance of common stock in conjunction with equity plans (in shares)   3,173      
Issuance of common stock in conjunction with equity plans 7,235 $ 3 7,232    
Issuance of common stock from Underwritten Public Equity Offering, net of issuance costs (in shares)   20,125      
Issuance of common stock from Underwritten Public Equity Offering, net of issuance costs 189,200 $ 20 189,180    
Share-based compensation expense 17,952   17,952    
Ending balance (in shares) at Mar. 31, 2023   249,803      
Ending balance at Mar. 31, 2023 $ 692,117 $ 250 2,314,146 (1,924) (1,620,355)
Beginning balance (in shares) at Dec. 31, 2023 267,744 267,744      
Beginning balance at Dec. 31, 2023 $ 701,304 $ 268 2,539,892 219 (1,839,075)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net loss (78,178)       (78,178)
Other comprehensive income (loss) (525)     (525)  
Issuance of common stock in conjunction with equity plans (in shares)   4,536      
Issuance of common stock in conjunction with equity plans 6,891 $ 4 6,887    
Share-based compensation expense $ 19,525   19,525    
Ending balance (in shares) at Mar. 31, 2024 272,280 272,280      
Ending balance at Mar. 31, 2024 $ 649,017 $ 272 $ 2,566,304 $ (306) $ (1,917,253)